Bukwang Pharm Stock Net Income
| 003000 Stock | 4,860 215.00 4.63% |
Bukwang Pharm fundamentals help investors to digest information that contributes to Bukwang Pharm's financial success or failures. It also enables traders to predict the movement of Bukwang Stock. The fundamental analysis module provides a way to measure Bukwang Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bukwang Pharm stock.
Bukwang |
Bukwang Pharm Company Net Income Analysis
Bukwang Pharm's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Bukwang Pharm Net Income | (916.62 M) |
Most of Bukwang Pharm's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bukwang Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Bukwang Pharm reported net income of (916.62 Million). This is much lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all Republic of Korea stocks is notably higher than that of the company.
Bukwang Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bukwang Pharm's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bukwang Pharm could also be used in its relative valuation, which is a method of valuing Bukwang Pharm by comparing valuation metrics of similar companies.Bukwang Pharm is currently under evaluation in net income category among its peers.
Bukwang Fundamentals
| Return On Equity | -0.0168 | |||
| Return On Asset | 0.0024 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.01 % | |||
| Current Valuation | 552.14 B | |||
| Shares Outstanding | 68.45 M | |||
| Shares Owned By Insiders | 30.26 % | |||
| Shares Owned By Institutions | 8.04 % | |||
| Price To Book | 2.45 X | |||
| Price To Sales | 3.55 X | |||
| Revenue | 182.49 B | |||
| Gross Profit | 75.55 B | |||
| EBITDA | 10.04 B | |||
| Net Income | (916.62 M) | |||
| Cash Flow From Operations | 26.52 B | |||
| Target Price | 29167.0 | |||
| Number Of Employees | 568 | |||
| Beta | -0.065 | |||
| Market Capitalization | 627.05 B | |||
| Total Asset | 397.42 B | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 397.42 B | |||
| Last Dividend Paid | 100.0 |
About Bukwang Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bukwang Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bukwang Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bukwang Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bukwang Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bukwang Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bukwang Pharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Bukwang Stock
| 0.66 | 005935 | Samsung Electronics | PairCorr |
| 0.67 | 005930 | Samsung Electronics | PairCorr |
| 0.71 | 005490 | POSCO Holdings | PairCorr |
Moving against Bukwang Stock
The ability to find closely correlated positions to Bukwang Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bukwang Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bukwang Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bukwang Pharm to buy it.
The correlation of Bukwang Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bukwang Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bukwang Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bukwang Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Bukwang Stock
Bukwang Pharm financial ratios help investors to determine whether Bukwang Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bukwang with respect to the benefits of owning Bukwang Pharm security.